Novelix Pharmaceuticals Gains 3.3% After Striking Commercial Deal with Germany’s GMBU

Synopsis: Novelix Pharmaceuticals Limited has signed an agreement with GMBU e.V., a biotechnology and ecology research institute based in Halle (Saale), Germany, to scale up astaxanthin production to commercial levels at its Hyderabad research facility, building on a pilot-scale programme first disclosed in October 2025.

A Hyderabad-based pharmaceutical company that was known as Trimurthi Limited until recently has disclosed a new commercial agreement with a European research partner, filing an intimation with BSE on June 3, 2026.

With a market capitalization of Rs. 114.70 crore, the shares of Novelix Pharmaceuticals Limited were last recorded at Rs. 54.40 per share, up 3.28 percent from its previous close of Rs.52.67. The stock is trading at a P/E of 44.96.

Novelix has entered into an agreement dated June 2, 2026 with GMBU e.V.  Gesellschaft für Modulare Biotechnologie und Ökologie, a German research institute headquartered in Halle (Saale) that specialises in modular biotechnology, microalgae cultivation, and ecological applications. The agreement’s stated purpose is the production scale-up of astaxanthin at commercial levels at Novelix’s research facilities in Hyderabad, following the success of a pilot-scale production programme. The pilot results had been separately disclosed to the exchange in October 2025.

The filing confirms there are no special rights between the parties, no promoter or group company interest in GMBU, and the transaction falls outside related-party definitions. No order value, commercial terms, or revenue timeline were disclosed.

What Astaxanthin Represents

Astaxanthin is a keto-carotenoid pigment produced naturally by microalgae most notably Haematococcus pluvialis and present in marine animals including salmon and krill. It is one of the most potent naturally occurring antioxidants known, with reported antioxidant activity significantly stronger than beta-carotene or vitamin C. The compound has wide applications in nutraceuticals, pharmaceuticals, cosmetics, and aquaculture feed. Natural astaxanthin from microalgae commands a significant price premium over its synthetic equivalent, with high-purity grades reaching several thousand dollars per kilogram in global markets.

The global astaxanthin market is currently dominated by synthetic producers, but demand for natural-source material has grown steadily as regulatory and consumer preference shifts toward clean-label ingredients.

The GMBU collaboration positions Novelix at the bioprocessing interface  leveraging German expertise in microalgae-based production systems to develop a commercially viable, India-based natural astaxanthin manufacturing capability. If the scale-up succeeds and the company establishes compliant production at meaningful volumes, the addressable opportunity is real. The gap between pilot success and commercially viable large-scale bioproduction, however, is substantial in both capital requirement and timeline.

Novelix is effectively a company in transition. Incorporated in 1994 as Trimurthi Limited, it operated for decades in financial intermediation before reorienting into pharmaceutical bulk drug trading and healthcare research analytics in FY24. The recent revenue surge from Rs. 31 crore in FY25 to a TTM run rate of approximately Rs. 128 crore  is driven by bulk drug trading activity, which carries wafer-thin operating margins of 2 percent or below. For the December 2025 quarter, standalone revenue was Rs. 48 crore against an operating profit of Rs. 1.31 crore. Net profit for the same quarter was Rs. 1 crore. ROCE stands at 0.96 percent and ROE at 0.64 percent  both essentially nil.

A more pressing concern is cash generation: operating cash flow was -Rs. 14 crore in FY25 despite reported profits, and debtor days stretched to 216  meaning the company is not collecting its receivables in any reasonable window. Other liabilities have ballooned from near-zero to Rs. 46 crore by September 2025, reflecting growing trade payables from the high-volume, low-margin trading model.

Governance Signals Require Scrutiny

Promoter holding has fallen from 66.56 percent in March 2025 to 49.43 percent in March 2026  a reduction of over 17 percentage points in a single year and the first time promoters have held below 50 percent. The public shareholding has crossed the majority threshold at 50.57 percent. On March 30, 2026, the company allotted 11.5 lakh equity shares at Rs. 20 per share, a substantial discount to the then-prevailing market price receiving Rs. 1.725 crore.

A non-executive director resigned on the same date, citing personal reasons. Each of these disclosures individually is explainable; collectively, they warrant careful attention from investors in a company that is simultaneously rebranding and pivoting business models.

Business Overview

Incorporated in 1994 and formerly known as Trimurthi Limited, Novelix Pharmaceuticals Limited is a Hyderabad-based micro-cap engaged in pharmaceutical research and the production and trading of bulk drugs, active pharmaceutical ingredients, and key starting materials. The company is debt-free as of its last reported balance sheet, which provides a degree of financial flexibility for early-stage research investments.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Novelix Pharmaceuticals Gains 3.3% After Striking Commercial Deal with Germany’s GMBU appeared first on Trade Brains.